Status:
ACTIVE_NOT_RECRUITING
Integrative Omics Approach to Allergic Rhinitis
Lead Sponsor:
Medical University of Graz
Collaborating Sponsors:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-100 years
Brief Summary
Nasal mucus and nasal epithelium are the first defense barriers against allergens. Various proteins are found in nasal mucus that play a role in allergic rhinitis and reflect immune response to allerg...
Eligibility Criteria
Inclusion
- pollen allergy verified by skin-prick test, blood tests for specific Immunoglobulin class E (RAST) and allergic rhinitis symptoms
Exclusion
- chronic infectious diseases
- bad overall health condition
- malignant disease,
- pregnancy
- long-term intake of nasal and/or systemic steroids
- antihistamines or leukotrienes
- allergen immunotherapy
- acute and/or chronic rhinosinusitis
- parallel participation in other studies
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03324100
Start Date
April 1 2018
End Date
January 1 2025
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ENT University Hospital Graz
Graz, Styria, Austria, 8036